Table 2 Changes in Expanded Disabilities Status Score and annualized relapse rate after treatment with mycophenolate mofetil.
Author | EDSS | Improved or stabilized EDSS (%) | ARR | Relapse free rate (%) | ||||
|---|---|---|---|---|---|---|---|---|
Median pre-treatment (range) | Median post-treatment (range) | P value | median pre-treatment (range) | Median post-treatment (range) | P value | |||
Jacob et al.11 | 6.0 (0.0–8.0) | 5.5 (0.0–10) | 0.17 | 91 | 1.15 (0.23–11.78) | 0.18 (0.00–1.50) | < 0.01 | 46 |
Huh et al.27 | 3.0 (0.0–8.0) | 2.5 (0.0–7.0) | 0.01 | 91 | 1.50 (0.30–11.80) | 0.00 (0.00–2.60) | < 0.01 | 60 |
3.2 (2.2)a | 2.7 (1.9)a | 2.6 (2.7)a | 0.5 (0.8)a | |||||
Mealy et al.32 | NR | NR | NR | NR | 2.61 (NR) | 0.33 (NR) | < 0.01 | 64 |
Torres et al.23 | 4.0 (3.0–6.5) | 5.0 (NR) | 0.46 | NR | 1.06 (0.84–2.31) | 0.39 (NR) | < 0.05 | 27 |
Chen et al.16 | 4.0 (0.5–8.0) | 2.0 (0.5–7.5) | < 0.01 | 95.2 | 1.20 (0.20–7.00) | 0.00 (0.00–1.70) | < 0.01 | 58.1 |
4.1 (2)a | 2.8 (2.1)a | 1.7 (1.2)a | 0.4 (0.5)a | |||||
Jeong et al.18 | 3.0 (0.0–7.0) | 2.0 (0.0–7.0) | < 0.01 | NR | 1.54c | 0.18c | < 0.01 | 64.7 |
Xu et al.19 | 2.0 (0.0–9.0) | 2.0 (0.0–8.5) | < 0.01 | 97.4 | 0.80 (0.00–8.00) | 0.00 (0.00–1.40) | 0.05 | NR |
2.7 (2)a | 2.0 (1.8)a | 1.0 (1.0)a | 0.1 (0.3)a | |||||
Chen et al.17 | 3.0 (0.5–8.0) | 2.0 (0.5–7.5) | < 0.01 | NR | 1.20 (0.10–7.00) | 0.00 (0.00–2.00) | < 0.01 | 56.2 |
Montcuquet et al.20 | ||||||||
Total | 4.0 (0.0–8.5) | 3.8 (0.0–10.0) | < 0.05 | NR | 1.00 (0.10–3.20) | 0.00 (0.00–3.00) | < 0.05 | 49.3 |
AQP4-pos | 4 (0–8.0) | 4 (0–8.5) | NR | NR | 1 (0.17–3.0) | 0.21 (0–1.12) | NR | 46.7 |
AQP4-neg | 3.5 (0–8.5) | 4 (0–10) | NR | NR | 0.9 (0.1–3.2) | 0 (0–0.8) | NR | 61.3 |
Huang et al.25 | 4.0 (0.0–8.5) | 3.0 (0.0–8.5) | < 0.01 | 90 | 1.02 (0.00–19.21) | 0.00 (0.00–2.44) | < 0.01 | 73 |
Jiao et al.15 | 3.0 (0.0–8.5) | 2.5 (0.0–8.5) | 0.01 | 87 | 1.40 (0.10–11.00) | 0.00 (0.00–2.80) | < 0.01 | 64 |
Mealy et al.24 | ||||||||
Total | NR | NR | NR | NR | NR | NR | NR | NR |
AQP4-pos | NR | NR | NR | NR | 1.79 | 0.29 | < 0.01 | 64.7 |
AQP4-neg | NR | NR | NR | NR | 1.45 | 0.30 | < 0.01 | 77.8 |
Yang et al.21 | 3.5 (2.0–8.5) | 2.0 (0.5–7.0) | < 0.01 | 100 | 0.90 (0.00–5.00) | 0.00 (0.00–2.40) | < 0.01 | 60 |
Zhou et al.26 | NR | NR | NR | NR | 1.00 (0.23—3.43) in adult patients | 0.00 (0.00—0.71) in adult patients | < 0.01 | 80% in adult patients |
0.98 (0.35–2.11) in pediatric patients | 0.28 (0–0.71) in pediatric patients | 50% in pediatric patients | ||||||
Poupart et al.22 | NR | NR | NR | NR | 0.71 (0.43–1.15)b | 0.20 (0.11–0.35)b | NR | NR |
